Saturday - May 16, 2026
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
May 05, 2026
BUFFALO, New York, May 5 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:

* * *

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

*

BUFFALO, N.Y.-Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of a phase 2 clinical trial (NCT06202066) evaluating SurVaxM in combinati . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products